Thermodynamics of Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs - Impact of a Second Drug on the Solution Phase Behavior and Implications for Combination Products

Journal of Pharmaceutical Sciences

Volumn 104, Issue 8, 2015, Pages 2583-2593

  Trasi, Niraj S ^a   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

amorphous; co amorphous; diffusion; fixed dose combination; formulation; liquid liquid phase separation; solubility; supersaturation

Indexed keywords

DICLOFENAC; FELODIPINE; LOPINAVIR PLUS RITONAVIR; PACLITAXEL; DRUG; DRUG COMBINATION; EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; SOLUTION AND SOLUBILITY;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; IN VITRO STUDY; MOLECULAR WEIGHT; PHARMACEUTICS; PHARMACIST; SOLUBILITY; THERMODYNAMICS; ULTRAVIOLET SPECTROSCOPY; CHEMICAL MODEL; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; DIFFUSION; DRUG COMBINATION; DRUG FORMULATION; KINETICS; PHYSICAL CHEMISTRY; SOLUTION AND SOLUBILITY;

DIFFUSION; DRUG COMBINATIONS; DRUG COMPOUNDING; EXCIPIENTS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPROMELLOSE DERIVATIVES; KINETICS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY; SOLUTIONS; THERMODYNAMICS;

EID: 84947039177     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24528     Document Type: Article

References (34)

1. Di L, Fish PV, Mano T,. 2012. Bridging solubility between drug discovery and development. Drug Discov Today 17 (9-10): 486-495.
2. Coan KED, Shoichet BK,. 2008. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130 (29): 9606-9612.
3. Owen SC, Doak AK, Wassam P, Shoichet MS, Shoichet BK,. 2012. Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol 7 (8): 1429-1435.
4. Frenkel YV, Clark AD, Das K, Wang YH, Lewi PJ, Janssen PAJ, Arnold E,. 2005. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J Med Chem 48 (6): 1974-1983.
5. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS,. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5 (6): 1003-1019.
6. Ilevbare GA, Liu H, Pereira J, Edgar KJ, Taylor LS,. 2013. Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir. Mol Pharm 10 (9): 3392-3403.
7. Ilevbare GA, Taylor LS,. 2013. Liquid-liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: Implications for solubility enhancing formulations. Cryst Growth Design 13 (4): 1497-1509.
8. Almeida E, Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS,. 2015. Assessment of the amorphous "solubility" of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm 12 (2): 484-495.
9. Mosquera-Giraldo LI, Taylor LS,. 2015. Glass-liquid phase separation in highly supersaturated aqueous solutions of telaprevir. Mol Pharm 12 (2): 496-503.
10. Van, Eerdenbrugh B, Raina S, Hsieh Y-L, Augustijns P, Taylor L,. 2014. Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments. Pharm Res 31 (4): 969-982.
11. Hsieh Y-L, Box K, Taylor LS,. 2014. Assessing the impact of polymers on the ph-induced precipitation behavior of poorly water soluble compounds using synchrotron wide angle X-ray scattering. J Pharm Sci 103 (9): 2724-2735.
12. Hsieh Y-L, Ilevbare G, Van Eerdenbrugh B, Box K, Sanchez-Felix M, Taylor L,. 2012. pH-induced precipitation behavior of weakly basic compounds: Determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res 29: 2738-2753.
13. Raina SA, Zhang GGZ, Alonzo DE, Wu J, Zhu D, Catron ND, Gao Y, Taylor LS,. 2014. Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs. J Pharm Sci 103 (9): 2736-2748.
14. Coan KED, Maltby DA, Burlingame AL, Shoichet BK,. 2009. Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem 52 (7): 2067-2075.
15. Zeldin RK, Petruschke RA,. 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53 (1): 4-9.
16. Lund W, Ed. 1994. The Pharmaceutical codex: Principles and practice of pharmaceutics. 12 ed. London: Pharmaceutical Press, pp 835-838.
17. Goddard ED, Turro NJ, Kuo PL, Ananthapadmanabhan KP,. 1985. Fluorescence probes for critical micelle concentration determination. Langmuir 1 (3): 352-355.
18. Raina S,. 2014. Phase behavior of supersaturation solutions of poorly soluble small molecules. PhD Thesis. West Lafayette: Purdue University.
19. Sotthivirat S, McKelvey C, Moser J, Rege B, Xu W, Zhang D,. 2013. Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364. Int J Pharm 452 (1-2): 73-81.
20. Stillhart C, Durr D, Kuentz M,. 2014. Toward an improved understanding of the precipitation behavior of weakly basic drugs from oral lipid-based formulations. J Pharm Sci 103 (4): 1194-1203.
21. Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carriere F, Mullertz A, Pouton CW, Porter CJH,. 2012. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. Mol Pharm 9 (11): 3286-3300.
22. Newman A, Nagapudi K, Wenslow R,. 2015. Amorphous solid dispersions: A robust platform to address bioavailability challenges. Ther Deliv 6 (2): 247-261.
23. Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S,. 2010. Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm 7 (5): 1431-1440.
24. Kwong AD, Kauffman RS, Hurter P, Mueller P,. 2011. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 29 (11): 993-1003.
25. Shah N, Iyer RM, Mair HJ, Choi DS, Tian H, Diodone R, Fahnrich K, Pabst-Ravot A, Tang K, Scheubel E, Grippo JF, Moreira SA, Go Z, Mouskountakis J, Louie T, Ibrahim PN, Sandhu H, Rubia L, Chokshi H, Singhal D, Malick W,. 2013. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 102 (3): 967-981.
26. Lindfors L, Forssen S, Skantze P, Skantze U, Zackrisson A, Olsson U,. 2006. Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations. Langmuir 22 (3): 911-916.
27. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U,. 2006. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22 (3): 906-910.
28. Banerjee S,. 1984. Solubility of organic mixtures in water. Environ Sci Technol 18 (8): 587-591.
29. Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Humbeeck JV, Van den Mooter G, Augustijns P,. 2010. Solubility increases associated with crystalline drug nanoparticles: Methodologies and significance. Mol Pharm 7 (5): 1858-1870.
30. Hsu ECH, Johnson JF,. 1974. Prediction of eutectic temperatures, compositions and phase diagrams for binary mesophase systemst. Mol Cryst Liq Cryst 27 (1-2): 95-104.
31. Nguyen DN, Van den Mooter G,. 2014. The fate of ritonavir in the presence of darunavir. Int J Pharm 475 (1-2): 214-226.
32. Laitinen R, Löbmann K, Grohganz H, Strachan C, Rades T,. 2014. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: Physical properties and stability. Mol Pharm 11 (7): 2381-2389.
33. Löbmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R,. 2012. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm 81 (1): 159-169.
34. Löbmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon KC,. 2013. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int J Pharm 453 (1): 80-87.